"CAPCIL". Adaptation posologique des traitements par aminoglycosides

in Acta Clinica Belgica. Supplementum (1999), 1

The objectives of the therapeutic drug monitoring are to assume the efficacy and inocuity of a medical treatment and the patient's observance. The administration of a drug to a patient is not always ... [more ▼]

The objectives of the therapeutic drug monitoring are to assume the efficacy and inocuity of a medical treatment and the patient's observance. The administration of a drug to a patient is not always performed in the same conditions and therefore treatment has to be adapted. When necessary, this one is very often based on empiric or very approximative notions and, more seldom, on results of plasmatic concentrations of the drug. The CAPCIL program allows the possibility to objectivate the medical decision and adapt the posology on the basis of two kinetic parameters: the biological half-life and the distribution volume. Indeed, most of pharmacokinetics modifications (drug interactions, diseases, ...) are affecting the two parameters. With basic informations so as height and weight, posology, treatment objectives and peak/trough plasmatic concentrations of the drug, the program is proposing several posology adaptation schemes. The example of a once-a-day administration of amikacin is discussed. [less ▲]

The Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves

in Veterinary Research Communications (1997), 21(7), 521-531

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet ... [more ▼]

The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet aggregation curves. WEB 2086 was infused intravenously into a group of 5 healthy male Friesian calves in a dose of 3 mg/kg over 1 min. The resultant inhibition peaked between 30 min and 1 h after administration of WEB 2086. The inhibition was significantly reduced after 3 h and became non-significant after 6 h, but maximal pre-treatment aggregation had not been restored by 24 h after the injection of WEB 2086. These results confirm previous results obtained in vitro and suggest that WEB 2086 is a potent antagonist of PAF activity in calves. They also suggest that further clinical studies with WEB 2086 in cattle are desirable. [less ▲]